This prospective observational study aims to investigate the effectiveness and safety of SBRT in the management of oligometastases from rare tumors. In addition, the study aims to identify potential differences in treatment efficacy and toxicity between different types of cancer and to provide valuable information on the use of SBRT in these contexts, potentially leading to better treatment options and outcomes for these patients.
ECOG PS 0 - 2
histologically confirmed diagnosis of rare solid tumors including melanoma, soft tissue sarcoma, head-neck tumors, gynaecological tumors, Merkel cell carcinoma, thymic carcinoma, gastrointestinal stromal tumors (GIST) and urothelial tumors
No limit to the number of metastases treated with SBRT but all active lesions must be treated with radical intent (primary tumor and metastases)
Synchronous and metachronous oligometastases, as well as oligorecurrent and oligoprogressive disease are allowed
prior treatment with radiation to the same metastatic site
inability to provide informed consent
contraindications to SBRT
Patients who underwent stereotactic body radiation therapy (SBRT) for oligometastases from rare solid tumors including melanoma, soft tissue sarcoma, head-neck tumors, gynaecological tumors, Merkel cell carcinoma, thymic carcinoma, gastrointestinal stromal tumors (GIST) and urothelial tumors
Cohort
Prospective
SBRT
Radiationstereotactic body radiation therapy (SBRT)
local control of treated metastases at 2 years after SBRT
local control of treated metastases at 2 years after SBRT
overall survival
overall survival
progression-free survival
time for which the patient has no trace oligometastatic progression
distant control
analyze the formation of new metastases distant from the oligometastatic site
toxicity rates
toxicity values caused by SBRT
Click on the lead sponsor to view all of their trials.
